Overview

A Biomarker-directed Study of XPro1595 in Patients With Mild to Moderate Alzheimer's

Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety and target engagement of XPro1595 in Alzheimer's patients with biomarkers of inflammation.
Phase:
Phase 1
Details
Lead Sponsor:
Inmune Bio, Inc.
Collaborator:
Alzheimer's Association